U.S. Stock News

NasdaqCM:RKLB
NasdaqCM:RKLBAerospace & Defense

A Look At Rocket Lab (RKLB) Valuation After Record Q1 Revenue And Major Multi Year Launch Deals

Rocket Lab (RKLB) is back in the spotlight after record first quarter 2026 earnings, with revenue of US$200.35 million, its largest multi year launch contract to date, and sharply higher guidance that has lifted investor interest. See our latest analysis for Rocket Lab. The earnings surprise and multi year launch deal have coincided with powerful momentum in the stock, with a 1 day share price return of 34.22% and a 30 day share price return of 54.99%. The 1 year total shareholder return is...
NYSE:BAC
NYSE:BACBanks

Is It Time To Reassess Bank of America (BAC) After Its 29.7% One Year Rally?

Investors may be wondering if Bank of America at around US$52.75 is still offering value or if most of the opportunity has already been priced in. The stock has had a mixed run, with a 1.3% decline over the last 7 days, a 4.9% gain over the last month, a 5.7% decline year to date, a 29.7% return over the past year, and a 108.2% return over 3 years. Recent coverage has focused on how large US banks are positioned as interest rate expectations shift and how regulatory discussions could...
NasdaqGS:HOPE
NasdaqGS:HOPEBanks

Assessing Hope Bancorp (HOPE) Valuation After Q1 2026 Growth And Territorial Bancorp Integration

Hope Bancorp (HOPE) drew fresh attention after its Q1 2026 report showed year-over-year growth in revenue and net income, supported by the integration of Territorial Bancorp, higher fee income, and ongoing share repurchases. See our latest analysis for Hope Bancorp. At a share price of US$12.52, HOPE has logged a 14.03% year to date share price return and a 28.10% total shareholder return over the past year. This suggests momentum has been building as investors weigh Q1 earnings, higher net...
NYSE:MSGE
NYSE:MSGEEntertainment

How Investors May Respond To Madison Square Garden Entertainment (MSGE) Profit Squeeze And Kalshi Branding Deal

Madison Square Garden Entertainment Corp. has reported its fiscal third-quarter 2026 results, with revenue rising to US$246.26 million while net income eased to US$5.11 million, and separately entered a multi-year partnership making Kalshi an Official Prediction Market Partner with naming rights to the sixth-floor Kalshi Concourse at Madison Square Garden. Despite higher expenses weighing on quarterly profit, management’s confidence in robust full-year growth and the Kalshi collaboration’s...
NasdaqCM:CLSK
NasdaqCM:CLSKSoftware

Is CleanSpark’s (CLSK) April Bitcoin Surge Quietly Redefining Its AI Infrastructure Ambitions?

In early May 2026, CleanSpark reported unaudited April production of 640 Bitcoin, with peak single-day output of 22.38 and average daily production of 21.33, alongside 50.0 EH/s of operational hashrate and 1.8 gigawatts of contracted power. Despite expanding Bitcoin production and outlining ambitions to build a multi-gigawatt AI infrastructure platform, analysts currently expect weaker near-term earnings and revenue, contributing to cautious sentiment around CleanSpark. Against this...
NYSE:FG
NYSE:FGInsurance

Is F&G Annuities & Life (FG) Priced Fairly After Recent Share Price Rebound?

If you are wondering whether F&G Annuities & Life is attractively priced or just looks cheap on the surface, its recent share performance gives a few clues worth unpacking. The stock last closed at US$27.08, with a 10.1% gain over the past month but a 9.0% decline over the last year and a 9.9% decline year to date, which may leave you questioning whether sentiment or fundamentals are in the driving seat. Recent coverage of F&G Annuities & Life has focused on its position as a listed insurer...
NasdaqGS:PAGP
NasdaqGS:PAGPOil and Gas

Plains GP Holdings (PAGP) FY 2025 Loss Challenges Bullish Profitability Narratives

Plains GP Holdings FY 2025 earnings recap Plains GP Holdings (PAGP) has just wrapped up FY 2025 with fourth quarter revenue of US$10.6 billion and a basic EPS loss of US$0.20, as investors weigh these headline figures against a current share price of US$23.63. Over recent quarters the company has seen revenue move between US$10.6 billion and US$12.5 billion. Basic EPS has ranged from a loss of US$0.44 in late 2024 to a small profit of US$0.04 in Q3 2025. This sets the stage for a close look...
NasdaqGS:DOX
NasdaqGS:DOXIT

Does Amdocs (DOX) Offer Opportunity After A 27.6% One-Year Share Price Decline

If you are wondering whether Amdocs stock is starting to look like value or a value trap, the current share price puts that question front and center. The stock closed at US$65.14 recently, with returns of 0.7% over 7 days, a 1.9% decline over 30 days, an 18.7% decline year to date and a 27.6% decline over the last year. This naturally raises questions about how the market is reassessing both growth potential and risk. Recent coverage has focused on how Amdocs fits into broader shifts in...
NYSE:KVUE
NYSE:KVUEPersonal Products

Kenvue Deal Progress And Restructuring Raise New Questions For Investors

Kenvue (NYSE:KVUE) is progressing toward a pending US$40b acquisition by Kimberly-Clark. Shareholders and major U.S. antitrust authorities have given their approvals. The company is pursuing its 2026 Restructuring Initiative alongside the transaction process. Kenvue, a consumer health company, is at the center of one of the larger proposed deals in its sector, with a pending US$40b acquisition by Kimberly-Clark. With shareholder and key U.S. antitrust approvals already in place, investors...
NYSE:SNOW
NYSE:SNOWIT

Is Snowflake (SNOW) Pricing Reflect Its Value After Recent Share Price Rebound?

Wondering whether Snowflake's current share price reflects its true worth or if the market is mispricing the stock? This article walks through the numbers so you can judge the valuation for yourself. Snowflake closed at US$153.72 recently, with a 12.6% return over the last 7 days and 3.0% over 30 days, set against a year-to-date return of a 29.1% decline and an 11.6% decline over the past year. These mixed returns sit alongside ongoing investor interest in data infrastructure and cloud...
NYSE:GWRE
NYSE:GWRESoftware

Do CEO Share Sales Undercut Sector-Driven Optimism Around Guidewire Software’s (GWRE) Investment Story?

In early May 2026, Guidewire Software participated in a broad software sector rally, with its move largely tied to stronger industry-wide investor interest rather than new company-specific announcements. At the same time, CEO Michael Rosenbaum’s continued share sales, alongside a year of only insider selling activity, raise questions about how leadership’s trading behavior aligns with market optimism around Guidewire’s positioning. We’ll now examine how Guidewire’s sector-driven momentum,...
NYSE:GIS
NYSE:GISFood

Did Elevating Dana McNabb to COO Just Recalibrate General Mills' (GIS) Management and Margin Narrative?

In early May 2026, General Mills promoted longtime executive Dana McNabb to Chief Operating Officer and board member, expanding her remit to all global operating segments and key functions including supply chain, innovation, and digital. This leadership shift, paired with refreshed incentives for top executives, highlights General Mills’ push to tighten execution, accelerate innovation, and reinforce long-term management continuity. We’ll now examine how McNabb’s expanded operational control...
NYSE:FND
NYSE:FNDSpecialty Retail

Why Floor & Decor (FND) Is Up 6.4% After New Stores Plan And $400 Million Buyback – And What's Next

In late April 2026, Floor & Decor Holdings, Inc. outlined fiscal 2026 earnings guidance, reported softer first‑quarter results, announced plans to open 20 new warehouse stores, and authorized a US$400 million share repurchase program without an expiration date. Taken together, these updates highlight a company balancing continued store expansion with shareholder returns, while signaling its view of long‑term demand for hard‑surface flooring in the United States. Next, we’ll examine how the...
NYSE:HUBS
NYSE:HUBSSoftware

Is HubSpot (HUBS) Pricing Look Attractive After A 63.1% One Year Share Price Fall

Wondering whether HubSpot at around US$243.72 is a bargain or a value trap? This article walks through what the current share price might be implying about the stock's worth. The stock has moved 9.9% over the last 7 days and 7.1% over the last 30 days, yet the return over the last year sits at a 63.1% decline and the year to date return is a 36.2% decline. Recent coverage has focused on HubSpot's position in marketing and sales software and how investors are reassessing growth stocks with...
NasdaqGS:DPZ
NasdaqGS:DPZHospitality

Is Domino's Pizza (DPZ) Attractive After A 29% Share Price Slide?

If you are wondering whether Domino's Pizza at around US$332 a share represents good value or is priced for perfection, this breakdown will help you judge whether the stock still fits your expectations. The stock has seen a 2.0% slip over the last week, a 9.7% decline over the last month, a 21.8% drop year to date and a 29.1% fall over the past year, which may change how you think about both risk and opportunity here. These moves sit against a backdrop in which investors are reassessing long...
NasdaqGS:ADTN
NasdaqGS:ADTNCommunications

A Look At ADTRAN Holdings (ADTN) Valuation After Improved Q1 Results And Updated Earnings Guidance

ADTRAN Holdings earnings and guidance move into focus ADTRAN Holdings (ADTN) has come under closer scrutiny after first quarter results showed higher revenue and a smaller net loss, alongside fresh second quarter revenue guidance that framed expectations for the rest of 2026. See our latest analysis for ADTRAN Holdings. Despite the latest quarterly update, the stock’s 1-day share price return of 7.38% and 7-day share price return of 17.75% were weak. However, the 90-day share price return of...
NYSE:AGRO
NYSE:AGROFood

Is Adecoagro (AGRO) Attractive After A 72% Rally And Recent Pullback?

Wondering if Adecoagro's recent share price puts it at a bargain or already reflects its strengths? This article breaks down what the current valuation is really telling you. The stock last closed at US$13.37, with a 72.3% return year to date and a 59.0% return over the past year. This is set against shorter term pullbacks of 5.1% over 7 days and 11.0% over 30 days that may signal shifting sentiment around risk and reward. Recent news around global food supply resilience, agricultural input...
NasdaqGS:APP
NasdaqGS:APPSoftware

Assessing AppLovin (APP) Valuation After Strong Q1 Beat And Raised Guidance

AppLovin (APP) just reported first quarter 2026 results that beat expectations, with revenue of US$1.84b and net income of US$1.21b. The stock reacted quickly as investors weighed the upgraded outlook. See our latest analysis for AppLovin. The latest 6.4% 1 day share price return and 21.6% 30 day share price return suggest momentum has picked up again after a weaker year to date, while the 1 year and multi year total shareholder returns remain very strong. If AppLovin's AI powered ad platform...
NYSE:NRG
NYSE:NRGElectric Utilities

A Look At NRG Energy (NRG) Valuation After Q1 2026 Earnings Surprise And Texas Gas Expansion

Q1 earnings surprise puts focus on NRG Energy stock NRG Energy (NRG) is back in the spotlight after Q1 2026 results showed revenue above expectations but earnings per share below forecasts, alongside reaffirmed full year guidance and an active build out of new Texas gas capacity. See our latest analysis for NRG Energy. The share price has retreated recently, with a 1 day share price return of a 5.83% decline and a year to date share price return of a 14.62% decline. This comes even though the...
NYSE:HE
NYSE:HEElectric Utilities

Hawaiian Electric Industries HE Earnings Turnaround Challenges Bearish Cash Flow Narratives

Hawaiian Electric Industries (HE) has reported fourth quarter FY 2025 revenue of US$805.8 million and basic EPS of US$0.23, rounding out a trailing twelve month EPS of US$0.71 on revenue of about US$3.1 billion. The company has seen quarterly revenue move from US$799.2 million and EPS of US$0.17 in Q4 2024 to US$805.8 million and EPS of US$0.23 in Q4 2025. Over the same period, the trailing twelve month line has shifted from revenue of US$3.2 billion and EPS of a US$10.42 loss in Q4 2024 to...
NYSE:XPEV
NYSE:XPEVAuto

XPeng (NYSE:XPEV) Valuation Check As April Deliveries Rise And AI Expansion Plans Advance

XPeng (XPEV) is back in focus after reporting April 2026 deliveries of 31,011 vehicles, a 13% month on month rise. The company also highlighted ongoing work on physical AI projects and global expansion plans. See our latest analysis for XPeng. Despite the recent April delivery update and ongoing work on physical AI and global expansion, XPeng’s short term share price return has been weak, with a 30 day share price return of a 9.7% decline and a year to date share price return of a 23.9%...
NasdaqGS:MXL
NasdaqGS:MXLSemiconductor

Is It Too Late To Consider MaxLinear (MXL) After A 6x One-Year Share Price Jump?

If you are wondering whether MaxLinear's recent share price move has left the stock looking expensive or still potentially interesting, the valuation story is where your attention should be. The stock last closed at US$82.37, with returns of 16.4% over 7 days, 347.4% over 30 days, 345.0% year to date and a very large 1 year gain that is more than 6x. These moves sit against a backdrop of ongoing interest in semiconductor stocks, with investors watching closely for updates on demand for...
NasdaqGS:ALMR
NasdaqGS:ALMRLife Sciences

Alamar Biosciences Revenue Jump And IPO Spotlight Neuro Focus Potential

Alamar Biosciences (NasdaqGS:ALMR) doubled its revenue in Q1 2026. The company launched two new products aimed at neurodegenerative disease research. Alamar completed an IPO in 2026 to support its next phase of growth. Alamar Biosciences operates in the life sciences tools and diagnostics space, where demand for more precise protein and biomarker measurement has been a key theme for researchers and drug developers. The new products focused on neurodegenerative disease research sit in an...
NasdaqGS:TNYA
NasdaqGS:TNYABiotechs

Tenaya Therapeutics (TNYA) Valuation Check As TN-401 Gene Therapy Data Approaches ASGCT 2026

Why the upcoming TN-401 data matters for Tenaya Therapeutics stock Tenaya Therapeutics (TNYA) is drawing attention as investors look ahead to new clinical safety and efficacy data for TN-401, its gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, at the ASGCT 2026 meeting. This late breaking oral presentation, together with additional abstracts on Tenaya’s gene therapy and gene editing programs, gives you fresh information to evaluate the company’s pipeline...